In CAR-T cell therapy, clinicians obtain T cell source material directly from a patient (autologous), or from a donor (allogeneic), modify them, and re-introduce them to the patient. Working with autologous cells can be complicated by insufficient source material quality or quantity, and expanding the cells to the requisite number takes time that the patient may not have. Allogeneic cells can be prepared in advance and mass produced, but they may be rejected by the patient, and in the worst case, begin attacking the patient’s own cells.
Vladimir Senyukov is the Director of BioAnalytical Development at Precision Biosciences, where he investigates the development and manufacturing of allogeneic CAR-T cell products. We spoke to him about working with allogeneic CAR-T cells to unlock their therapeutic potential.
Using single-cell functional proteomics for CAR-T cell therapy development
Senyukov’s goal is to learn what actually drives a cell to be polyfunctional – to produce ...
